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Background: Interventional diagnostic procedures are established for several diseases in medicine. Despite the
KDOQI guideline recommendation for histological diagnosis of kidney disease to enable risk stratification, its
optimal time point has not been evaluated. We have therefore analyzed whether histological diagnosis of
glomerulonephritis (GN) at an early stage of chronic kidney disease (CKD) is associated with different outcome
compared to diagnosis at a more advanced stage.
Methods: A cohort of 424 consecutive patients with histological diagnosis of GN were included in a retrospective
data analysis. Kidney function was assessed by glomerular filtration rate (GFR) estimation at the time point of kidney
biopsy and after consecutive immunosuppressive therapy. Censored events were death, initiation of dialysis or
kidney transplantation, or progression of disease, defined as deterioration of CKD stage ≥1 from kidney biopsy to
last available kidney function measurement.
Results: Occurrence of death, dialysis/transplantation or progression of disease were associated with GFR and CKD
stage at the time of kidney biopsy (p< 0.001 for all). Patients with CKD stage 1 and 2 at kidney biopsy had fewer
endpoints compared to patients with a GFR of <60 ml/min (p< 0.001).
Conclusion: Kidney function at the time point of histological GN diagnosis is associated with clinical outcome,
likely due to early initiation of specific drug treatment. This suggests that selection of therapy yields greatest benefit
before renal function is impaired in GN.Background
The time points when interventions should be recom-
mended have been investigated and established in multiple
fields of medicine. For patients with renal disease kidney
biopsy can be necessary for diagnosis and treatment selec-
tion. Technical advances (e.g. real-time ultrasound and
automated biopsy needles) improved the general imple-
mentation of this procedure [1]. Major complications
occur in less than <0.1% of kidney biopsies [1-4].
The incidence of chronic kidney disease (CKD) is
increasing in the western communities and outcomes are
poor. The number of patients with CKD undergoing main-
tenance hemodialysis is expected to rise further [5]. Com-
plications of decreased kidney function or concomitant* Correspondence: dominik.haider@meduniwien.ac.at
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reproduction in any medium, provided the orcardiovascular disease (CVD) may be preventable by early
diagnosis and treatment [6]. However, CKD is frequently
underdiagnosed and undertreated [7-9].
There is insufficient evidence to conclude best timing
of invasive diagnostic procedures in patients with several
kidney diseases. An early kidney biopsy may be of par-
ticular interest for those patients where disease classifi-
cation is based on histological diagnosis and where
the disease progression can be mitigated by treatment.
While current guidelines have established the medical
management of glomerulonephritis (GN) including the
necessity of histological analysis and administration of
immunosuppressive therapies, it is yet unclear if early
diagnosis may result in prevention of CKD development
in this heterogeneous group of patients.
We therefore performed a retrospective analysis to
address the question if diagnosis of GN from an early
kidney biopsy before kidney function impairment, as
classified by glomerular filtration rate (GFR) and CKDLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Baseline characteristics and co-morbidities in
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diagnosis of GN at a later CKD stage.
Methods
Retrospective data from 917 consecutive patients who
underwent kidney biopsy between 1992 and 2009 were
identified. Among those 171 patients had diabetic
nephropathy or secondary focal segmental glomerulo-
sclerosis (FSGS) and were excluded. From 322 patients
no follow up was available. Thus, 424 patients with a
histological diagnosis of GN who received immuno-
suppressive therapy were included into the analysis
(Figure 1). The study protocol and data handling pro-
cedure was approved by the Ethics Committee of the
Medical University of Vienna.
Patients were characterized by CKD-stages according
to their kidney function prior to biopsy and during fol-
low up. Glomerular filtration rate (GFR) estimation was
calculated via the MDRD formula [10]. Primary outcome
variables were progression of disease, dialysis/kidney
transplantation or death. Progression of kidney disease
was defined as deterioration of CKD stage ≥1 from the
time of kidney biopsy to last kidney function measure-
ment. Stable disease was regarded as constant or
improved CKD stage from the time of kidney biopsy to
last available kidney function measurement, without
an episode of dialysis or kidney transplantation. After
kidney biopsy patients received induction therapy with
cortisone with or without cyclophosphamide as immu-
nosuppressive therapy according to their histological
diagnosis and adjusted to their body weight. Systolic
blood pressure was set at ≤130 mmHG. The amount of
patients with the respective antihypertensive therapy:
ACE-inhibitors/AT2-blockers: 190/96 (withdrawal because
of systolic BP< 110 mmHg); ß-Blocker: 77; Ca-channel-
blockers:106; alpha-blockers:53.
Indications for kidney biopsy were proteinuria, micro-
hematuria or increments in serum creatinine alone or
in combination. The histological classification of GN917 patients with kidney 
biopsy 
171 patients with the 
diagnosis diabetic 
nephropathy or secondary 
FSGS 
746 patients with GN 
322 patients without 
follow up information 
424 patients with GN and 
clinical follow up 
Figure 1 Subject identification chart.was derived from laboratory reports of the Department
of Pathology at the Vienna General Hospital, which has
also been used for clinical decision making in these
patients. Baseline characteristics and co-morbidities are
shown in Table 1.
Statistical analysis
For data description results are presented as median and
25–75% interquartile range or mean and standard devi-
ation as appropriate. For univariate analysis the Mann
Whitney U test or the chi-squared test were used as
appropriate. The Kaplan-Meier method was used to
determine event-free survival and the log rank test was
used to compare survival between subgroups. Univariate
and multivariate regression analysis were performed
using the Cox proportional hazard regression model
to determine the effect of various variables on survival.
Potential predictors were defined a priori or based on
associations in the univariate analysis at a conservative
threshold (p< 0.10). The Hosmer-Lemeshow test was
used to assess goodness of model fit. We used SPSS
Statistics for data management and calculations. A two
sided p-value less than 0.05 was considered statistically
significant. The authors performing the data analysis
(D.G.H. and V.F.) were masked and were not involved
in the data acquisition.Systemic Lupus Erythematosus 51
Goodpasture Syndrome 7
Co-Morbidities
Diabetes Mellitus Type 1 4
Diabetes Mellitus Type 2 27
Hypertension 237
Coronary Heart Disease 28





Chronic Obstructive Pulmonary Disease 27






























































Figure 2 Distribution of mortality, dialysis/transplantation and progression of disease according to diagnosis and overall.
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Figure 3 Cumulative survival of patients with CKD stages 1+ 2
(solid line, n = 172) compared with patients with CKD stages 3,
4 and 5 (dotted line, n = 248) (Kaplan Meier, p=0.001; Chi-
Square-Test).
Figure 4 Cumulative survival of patients with stable (solid line,
n = 209) or progressive kidney disease (dotted line, n = 215)
(Log Rank test p< 0.0001). Progression of kidney disease was
defined as deterioration of CKD stage ≥1 from the time of kidney
biopsy to last kidney function measurement.
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The median observation time was 4.0 years (interquartile
range, IQR: 1.3;8.4 years). Overall, 106 (25%) patients
had CKD stage 1, 65 (15%) patients had CKD stage 2,
109 (26%) patients had CKD stage 3, 70 (17%) patients
had CKD stage 4, and 74 (17%) patients had CKD stage
5 before kidney biopsy. Estimated GFR slightly improved
in pooled analysis during the observation period from
45 ml/min (IQR: 23–80) to 51 ml/min (IQR: 25–83) after
1 month and to 52 ml/min (IQR: 29–76) at the end of
the observation period (P< 0.05 vs baseline). In subgroup
analysis significant improvements in GFR were seen after
one month for patients with vasculitis, IgA-Nephropathy
and Systemic Lupus Erythematosus (SLE) (all p< 0.05),
and at study end for patients with membranous GN, IgA-
Nephropathy and vasculitis (all p< 0.05).
Kidney function remained stable or improved in 216
(51%) patients. 208 patients had a progression of disease
(49%). Of these, 144 patients underwent dialysis (34%)
and 98 patients had subsequent kidney transplantation
(23%). 47 patients (11%) died during the observation
period. Distribution of mortality, dialysis/transplantation
and progression of disease according to histological diag-
nosis is shown in Figure 2.
Data of quantitative proteinuria one month after initi-
ation of immunosuppressive therapy was accessible in
174 patients. Of these 42 patients (24%) had proteinuria
of >3.5 g/d. Univariate regression analysis including
underlying diseases, age, sex and GFR identified mem-
branous GN and vasculitis as predictors for progression/
persistence of proteinuria (for both p< 0.01). Multivari-
ate regression analysis detected membranous GN as an
independent predictor for progression/persistence of
proteinuria (p< 0.01).
To assess whether the time point of kidney biopsy is
associated with survival, patients with a GFR ≥60 ml/ml
(CKD stage 1 and 2; n= 171) were compared with the
group of subjects with impaired renal function at CKD
stages 3, 4 and 5 (n= 253). Patients undergoing kidney
biopsy at CKD stage 1 and 2 had a markedly better over-
all event-free survival than the group of patients with
higher CKD stages (Figure 3). Dialysis or kidney trans-
plantation was less frequent in patients with CKD stage
1 and 2 after immunosuppressive therapy than other
patients with GN (p< 0.01). Disease progression was
associated with increased mortality during follow-up
(Figure 4).
CKD stage at kidney biopsy was associated with favor-
able renal outcome. In particular, CKD stage was pre-
dictive for mortality (AUC: 0.65 for both), dialysis/
transplantation (AUC: 0.71 and 0.73), and progression of
disease (AUC: 0.58 and 0.6) (Figure 5).
Multivariate regression analysis revealed that mortality
was associated with CKD stages, but not with dialysis/transplantation and progression of disease (Table 2). In-
dependent predictors for dialysis/transplantation were
CKD stage and minimal change GN in multivariate re-
gression analysis (Table 2b). Minimal change GN was
the only predictor for progression of disease in a multi-
variate model (Table 2c). Further, mortality was asso-
ciated with age and MP-GN.
Discussion
In this large sample of patients with different etiology
of GN an early time point of kidney biopsy was asso-
ciated with smaller declines in kidney function, a less







Figure 5 ROC-Analysis for CKD and GFR at the time point of kidney biopsy as predictors for mortality (A), dialysis (B) and progression
of disease (C).
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was a strong predictor of salutary outcome in patients
with CKD.
Overall, immunotherapy prevented deterioration of
kidney function in approximately half of the cohort of
patients with GN. This treatment response is compar-
able with that shown across the groups of subjects with
different histological diagnoses of GN in other studies
[11-17]. When patients were in CKD stage 1 or 2 pro-
gression of disease was less likely during therapy indicat-
ing that early specific drug treatment is essential for
clinical benefit, independent of the underlying classifica-
tion of GN. However, this effect was not consistent
and the patients with membranoproliferative GN had
the worse outcome. This is in accordance with other
data [18].
The association of CKD stages with mortality is com-
parable with data obtained in the general population
[18,19]. Our data demonstrates that early biopsy-guidedinitiation of therapy might result in a profound advan-
tage for patients to preserve kidney function. Patients at
CKD stage 1 and 2 had a significantly better outcome
compared with other patients. This is also in good agree-
ment with studies in patients with high cardiovascular
risk [20,21].
Our analysis revealed strong associations of mortality
with age. This is in accordance with other data regarding
the progression of disease [22]. Kidney biopsy has
demonstrated a clear benefit also for elderly patients
with acute kidney failure in an observational study [23].
These findings are extended by our results in patients
with GN. Therefore, kidney biopsy should be considered
independent of age in all patients with suspected GN.
Current indications for kidney biopsy are derived from
surveys and expert opinions [24,25]. This study adds
important evidence based on a large cohort analysis.
A limitation of the analysis of efficiency of drug treat-
ment is the fact that response rates have improved over
Table 2 Multivariate Cox-Regression for mortality (A), for
dialysis/transplantation (B) and for progression of









Systemic Lupus Erythematosus 0.173





Minimal Change GN 0.04
Systemic Lupus Erythematosus 0.09
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new drugs. However, this does not limit the principal
finding of this observational study, because no therapy
was withheld and all patients had access to optimized
medical treatment provided by the national sickness
fund during the observation period. This study has not
compared individual treatments within groups of
patients with different GN entities and numbers within
subgroups are too small for such analysis. While this is a
large study, the median follow-up is 4 years, which may
not be long enough to observe clinically relevant out-
come or progression in diseases such as IgA nephropa-
thy or membranous nephropathy. A further limitation of
our study is that only a controlled interventional trial may
demonstrate if baseline differences may be accounted for
the results seen. However, ethical concerns prevent con-
duct of such a trial.
Conclusions
In summary, kidney biopsy at CKD stages 1 or 2 and
consecutive therapy preserves kidney function and pre-
vents disease progression through early initiation of
therapy. The present observational data clearly supports
the concept of early kidney biopsy in patients with sus-
pected GN.
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